(Q24241065)

1

0 references

Rachel Churchill

7

0 references

Atsuo Nakagawa

Atsuo Nakagawa

5

0 references

Hugh McGuire

6

Hugh McGuire

0 references

Toshi A Furukawa

3

Toshi A Furukawa

0 references

Alessandra Signoretti

4

Alessandra Signoretti

0 references

Claudio Santilli

2

Cochrane Database of Systematic Reviews

Claudio Santilli

0 references

language of work or name

English

0 references

publication date

2009

0 references

published in

0 references

issue

2

0 references

page(s)

CD006532

0 references

cites work

Venlafaxine versus other anti-depressive agents for depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Fluvoxamine versus other anti-depressive agents for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Milnacipran versus other antidepressive agents for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Fluoxetine versus other types of pharmacotherapy for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Efficacy of antidepressants in adults

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

A rating scale for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

St John's wort for major depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Amitriptyline versus other types of pharmacotherapy for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Measuring inconsistency in meta-analyses

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Imputing missing standard deviations in meta-analyses can provide accurate results

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Scope and impact of financial conflicts of interest in biomedical research: a systematic review

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Detecting skewness from summary information

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

A New Depression Scale Designed to be Sensitive to Change

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Antidepressants and their onset of action: a major clinical, methodological and pronostical issue

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Evaluation of networks of randomized trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Treatment and prevention of mental disorders in low-income and middle-income countries

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Can discrete event simulation be of use in modelling major depression?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Are all antidepressants really the same? The case of fluoxetine: a systematic review.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Are we going to increase the use of antidepressants up to that of benzodiazepines?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Australian and New Zealand clinical practice guidelines for the treatment of depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

"Wish bias" in antidepressant drug trials?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Industry sponsorship and authorship of clinical trials over 20 years

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

SSRIs versus other antidepressants for depressive disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

A systematic review of newer pharmacotherapies for depression in adults: evidence report summary

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

A consumer's guide to subgroup analyses

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder

30 May 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Amitriptyline for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Citalopram versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Placebo in clinical trials for depression: complexity and necessity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Clinician's judgments of mental health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Sertraline versus other antidepressive agents for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Milnacipran versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Duloxetine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Fluvoxamine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Full disclosure and the funding of biomedical research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Mirtazapine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Imputing response rates from means and standard deviations in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006532.PUB2

Escitalopram in the treatment of depressed elderly patients

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164382

Network meta-analysis for indirect treatment comparisons

29 November 2018

1 reference

12 December 2020

The uncertainty principle and industry-sponsored research

1 reference

12 December 2020

Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports

1 reference

12 December 2020

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association

1 reference

12 December 2020

Physician communication about the cost and acquisition of newly prescribed medications

1 reference

12 December 2020

10.1002/14651858.CD006532.PUB2

Identifiers

DOI

1 reference

1 reference

1 reference

PubMed publication ID

19370639

1 reference